Literature DB >> 21386127

[Patients' perspective on Parkinson disease therapies: results of a large-scale survey in Japan].

Ken-Ichi Fujimoto1, Miho Murata, Nobutaka Hattori, Tomoyoshi Kondo.   

Abstract

Parkinson's disease (PD) affects 145,000 people in Japan. Most of these patients are treated with levodopa in combination with other anti-PD therapies. In order to maximize efficacy and patient satisfaction, this survey was conducted to investigate patients' perspective of current PD management in Japan. This survey was conducted in 2008 by questionnaire (3,935) and interview (407). The majority of responders were members of the Japan PD Association. Severity of PD, medication, impact of wearing-off, and patients' attitudes to therapy were assessed. Most patients (95%) were on levodopa, with an average dose of 370 mg/day. Although dose increased with duration of treatment, the majority of patients remained within 300-400 mg/day. Patients with wearing-off were less satisfied with their therapy than those without wearing-off (36 vs 49%). Most patients are less concerned by mild dyskinesias. Hallucination is the most distressing side effect. For patients preferring mobility over dyskinesia, levodopa should be dosed sufficiently, and possibly titrated, to maximize clinical benefit and patient satisfaction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21386127

Source DB:  PubMed          Journal:  Brain Nerve        ISSN: 1881-6096


  2 in total

1.  Development and Validation of the Parkinson's Disease Medication Beliefs Scale (PD-Rx).

Authors:  Jori E Fleisher; Nabila A Dahodwala; Sharon X Xie; Mark Mayo; Daniel Weintraub; Joshua Chodosh; Judy A Shea
Journal:  J Parkinsons Dis       Date:  2016-04-02       Impact factor: 5.568

2.  Treatment Satisfaction and Its Influencing Factors in Parkinson's Disease: A Web-Based Survey of Patients and Physicians in Clinical Practice in Japan.

Authors:  Masahiro Nomoto; Ayako Hayashi; Hiroyuki Ida; Masaki Arai
Journal:  Parkinsons Dis       Date:  2022-02-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.